Status: Recruiting
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in pediatric and adult subjects (age 4-55 years) diagnosed with Lennox Gastaut Syndrome (LGS).
Participants needed: 252
Trial details
Phase: Phase 3Age: 4-55Biological sex: AllType: InterventionalSponsor: SK Life Science, Inc.Updated: Jul 24, 2025Locations: 71
Eligibility criteria
Evidence of more than one type of seizure, of which at least one should be an at... [+14]
Etiology of subject's seizures is a progressive neurologic disease. Subjects wit... [+26]